Efficacy - Entresto
ENTRESTO ® achieved superior outcomes vs Enalapril in the largest trial ever conducted in HF
- Twitter Linkedin Facebook Pinterest Google plus
Mechanism of Action - Entresto
Sacubitril/valsartan, a first-in-class ARNI, delivers simultaneous inhibition of neprilysin and blockade of the AT1 receptor. Sacubitril/valsartan is a sodium salt complex comprising sacubitril (AHU377), a prodrug, which is further metabolized to the...
Twitter Linkedin Facebook Pinterest Google plusDosing - Entresto
Dose regimen Oral use Twice daily dose. Can be taken with or without food; The tablets must be swallowed with a glass of water. Tablet strength makes interim dose adjustment easy. If a dose is missed, the patient should take the next...Twitter Linkedin Facebook Pinterest Google plusSafety Profile - Entresto
ENTRESTO ® demonstrated comparable safety and tolerability vs EnalaprilTwitter Linkedin Facebook Pinterest Google plusPatient Resources - Cosentyx PsA
Dose recommendation - Jakavi
Mechanism of Action - Jakavi
Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 a nd for myelofibrosis (MF). 6
JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Jakavi
Mechanism of Action - Kisqali
Ribociclib is a selective inhibitor of cyclin-dependent kinase (CDK) 4 and 6, resulting in 50% inhibition (IC50) values of 0.01 (4.3 ng/ml) and 0.039 μM (16.9 ng/ml) in biochemical assays, respectively. These kinases are activated upon binding to D-...
Twitter Linkedin Facebook Pinterest Google plusPatient Resources - Scemblix
×